News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Dupixent (dupilumab) Becomes the First Biologic Medicine Approved in Japan for Chronic Obstructive Pulmonary Disease (COPD)
Saturday, March 29, 2025Regeneron Pharmaceuticals Inc and Sanofi have received marketing and manufacturing authorisation from Japans Ministry of Health Labour and Welfare MHLW for Dupixent dupilumab as a treatment for adults with chronic obstructive pulmonary disease COPD t...
Dupixent® (dupilumab) Receives Approval in Japan as the First Biologic Medicine for Chronic Obstructive Pulmonary Disease (COPD)
Friday, March 28, 2025Regeneron Pharmaceuticals Incand Sanofi have announced that Japans Ministry of Health Labour and Welfare MHLW has granted marketing and manufacturing authorisation for Dupixent dupilumab to treat adults with chronic obstructive pulmonary disease COPD...
Intellia Therapeutics Receives FDA RMAT Designation for Nexiguran Ziclumeran in Treating ATTR Amyloidosiswith Cardiomyopathy
Thursday, March 27, 2025Intellia Therapeutics Inc a clinicalstage gene editing company focused on CRISPRbased therapies has announced that the US Food and Drug Administration FDA has granted Regenerative Medicine Advanced Therapy RMAT designation to nexiguran ziclumeran
Ionis Expands Partnership with Sobi for Olezarsen Commercialisation Outside the U.S.
Thursday, March 27, 2025Ionis Pharmaceuticals Inc has entered into a licence agreement granting Sobi exclusive rights to commercialise olezarsen outside the US Canada and China Ionis will retain responsibility for olezarsens commercialisation in the US
Porosome Therapeutics Announces Major Breakthrough in Alzheimer’s Disease Research and Treatment
Wednesday, March 26, 2025Porosome Therapeutics Inc has revealed new findings on the secretory dysfunction linked to Alzheimers disease and advancements in therapeutic neuronal nanomachines These developments could reshape research and treatment strategies for the condition
Sermonix and Regor Collaborate to Enhance rCARD Platform for Identifying New Breast Cancer Treatments
Tuesday, March 25, 2025Sermonix Pharmaceuticals a privately owned biopharmaceutical company focused on developing targeted therapies for metastatic breast cancer mBC has announced a strategic collaboration with Regor Therapeutics Group
The United Laboratories and Novo Nordisk sign exclusive licensing deal for UBT251, a GLP-1/GIP/glucagon triple receptor agonist.
Monday, March 24, 2025The United Laboratories International Holdings Limited TUL and Novo Nordisk have signed an exclusive licensing agreement for UBT a triple agonist targeting GLP GIP and glucagon receptors This drug is in earlystage clinical development for obesity typ...
Candel Therapeutics and IDEA Pharma Form Partnership to Support CAN-2409 Commercialisation
Friday, March 21, 2025Candel Therapeutics Inc a clinicalstage biopharmaceutical company developing biological immunotherapies for cancer treatment has entered into a strategic commercial partnership with IDEA Pharma a division of SAI MedPartners
Pint Pharma Received ANVISA Approval for BESREMi® to Treat Polycythemia Vera
Friday, March 21, 2025Pint Pharma and PharmaEssentia have received approval from ANVISA Brazilian National Health Surveillance Agency for BESREMi ropeginterferon alfab to treat adult patients with Polycythemia Vera PV
MAIA Biotechnology Receives USAN Council Approval for ‘Ateganosine’ as Generic Name for Anticancer Agent THIO
Thursday, March 20, 2025MAIA Biotechnology Inc a clinicalstage biopharmaceutical company focused on targeted immunotherapies for cancer has received approval from the United States Adopted Names USAN Council for ateganosine as the nonproprietary generic name for its lead mo...
